Evaluation of Safety and Efficacy of Three Flavors of Supportan® Drink in Cancer Patients in Taiwan

Inclusion Criteria: 1. Patients receiving chemotherapy and/or radiotherapy, or immunotherapy, or targeted therapy; 2. Patient with diagnosed cancer of any type (e.g., head and neck cancer, lung cancer, digestive tract cancer, breast cancer); 3. Patient with or at risk of malnutrition defined as meeting Malnutrition Universal Screening Tool (MUST) with score ≥2; 4. Capable of using oral nutritional supplementation; 5. Written informed consent from patient. Exclusion Criteria: 1. Patient with documented diagnosis of liver, kidney or heart disease in the hospital's electronic medical record (EMR); severity of disease evaluated by Investigator as not being suitable to participate in this study; 2. Current alcohol or substance abuse as assessed by Investigator; 3. Patient had a stroke in the past year and is after Investigator assessment judged as not yet clinically stable at the time of screening; 4. Patients who are diagnosed with mental illness or depression assessed by the Investigator as too severe for being suitable to participate in this study; 5. Pregnant or breastfeeding woman; 6. Allergic to any ingredient of the investigational products; 7. Patients receiving or having received standard (not disease specific) oral nutritional supplements (ONS), standard enteral formula/tube feeding or standard parenteral cancerspecific nutrition supplements in the last 3 days; 8. Patients receiving or having received ONS, enteral formula/tube feeding or parenteral nutrition with high fish oil or high EPA/DHA content (above 1 g/day) in the last 28 days; 9. Current use of medication, food supplements or ONS containing more than 500 mg of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)/day or fish oil capsules/supplements containing more than 500 mg EPA and DHA/day at screening; 10. Transfusion of blood products within 1 week before screening; 11. Surgery scheduled during the trial; 12. Participation in other clinical trials using investigational drugs within 14 days before the start of the trial or during the trial.